Belgium· BE-AMP-SAM666105-00

Poherdy 420 mg

A pertuzumab product containing pertuzumab, registered in Belgium by Organon. The same ATC class is registered in 14 of our 19 countries.

ATC L01FD02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedPoherdy 420 mgATCL01FD02REGISTER NO.BE-AMP-SAM666105-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Pertuzumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FD02 (pertuzumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Pertuzumab · ATC L01FD02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Pertuzumab
Manufacturer
Organon
Country
Belgium (BE)
ATC code
L01FD02
ATC class
Pertuzumab
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for pertuzumab.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pertuzumab · interactions on record

2 records

  • 2 moderate

Most severe, free to view

  • IdelalisibL01EM01moderate
  • IdelalisibL01XX47moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pertuzumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pertuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Perjeta, Poherdy
  • Liechtenstein · Perjeta, Poherdy
  • Norway · Perjeta, Poherdy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/adcca925-5ac7-45e0-9419-b4eb95d5efa1
GET /v1/drugs/adcca925-5ac7-45e0-9419-b4eb95d5efa1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Poherdy 420 mg",
  "name_fr": "Poherdy 420 mg",
  "name_nl": "Poherdy 420 mg",
  "amp_code": "SAM666105-00",
  "strengths": [
    "30.0000",
    "30.0000",
    "30.0000",
    "0.2000"
  ],
  "pack_count": 1,
  "substances": [
    "Pertuzumab",
    "Sorbitol",
    "Polysorbate 20"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Pertuzumab",
  "authorisation_numbers": [
    "EU/1/25/2008/001"
  ]
}

See everything about pertuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.